{"id":4324,"date":"2019-09-20T05:50:01","date_gmt":"2019-09-19T19:50:01","guid":{"rendered":"https:\/\/doseme-rx.com\/?p=4324"},"modified":"2021-04-13T11:19:49","modified_gmt":"2021-04-13T01:19:49","slug":"doseme-rated-most-user-friendly-in-clinical-study","status":"publish","type":"post","link":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study","title":{"rendered":"DoseMe Bayesian Forecasting Method Receives Rating of Most User-Friendly in Clinical Study"},"content":{"rendered":"<p><strong>Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC)<\/strong>, a healthcare technology company advancing the field of medication safety, announced an independent study evaluating Bayesian Forecasting (BF) programs found TRHC\u2019s DoseMe BF program &#8211; <a href=\"http:\/\/doseme-rx.com\">DoseMeRx<\/a> &#8211; to be the most user-friendly.<\/p>\n<p>BF programs, such as DoseMeRx, use patient data and laboratory results to estimate a patient\u2019s ability to process a drug. Using a published population model, the program adjusts the pharmacokinetic parameters and provides an individualized dosing recommendation to reach a therapeutic target.<\/p>\n<p>Published in the <em>British Journal of Clinical Pharmacology <\/em>(BJCP), the purpose of <a href=\"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full\/10.1111\/bcp.14066\">the study<\/a> was to evaluate three BF programs, of which DoseMeRx was one, on their user-friendliness and common liked and disliked features through a study of hospital pharmacists. Twenty-seven clinical pharmacists across three teaching hospitals, that were not currently using a BF program, participated.<\/p>\n<p>\u201cA potential barrier to the use of the Bayesian forecasting method of dose individualization is the availability of an easy-to-use program,\u201d said TRHC Chairman and CEO Calvin H. Knowlton, PhD. \u201cWe are pleased and proud DoseMeRx has been positively evaluated as user-friendly in a clinical setting. It supports the evidence these programs are designed for clinical implementation.\u201d<\/p>\n<p>This is the first ever user-friendly evaluation of these programs with end-users, according to the BJCP article titled, \u201cAn Evaluation of the User-friendliness of Bayesian Forecasting in a Clinical Setting\u201d.<\/p>\n<p>\u201cDoseMeRx was the favored software across all user-friendly categories, most notably in the ease of data entry and clarity of understanding and interpreting recommendations presented,\u201d stated DoseMe CEO Charles Cornish. \u201cWe built DoseMeRx with two fundamental pillars at its core: proven science and amazing usability. Clinicians do not have seconds to waste, so usability is key to the clinical impact of decision support tools like DoseMeRx. The easier our software is to use, the more it is used and supports clinicians in improving patient safety, clinical outcomes and workflows\u201d.<\/p>\n<p>DoseMe\u2019s precision dosing software, DoseMeRx, was developed specifically for clinical practice. It is a simple, yet powerful tool helping healthcare providers calculate the optimal dose of drugs monitored by therapeutic drug monitoring to streamline operations, reduce adverse drug events, decrease costs, and improve patient outcomes.<\/p>\n<p><strong>About Tabula Rasa HealthCare<\/strong><\/p>\n<p>Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.&nbsp; Medication risk management is TRHC\u2019s lead offering, and its cloud-based software applications, including EireneRx\u00ae and MedWise\u00ae, provide solutions for a range of payers, providers, and other healthcare organizations.&nbsp; <a href=\"http:\/\/www.tabularasahealthcare.com\">www.tabularasahealthcare.com<\/a>.<\/p>\n<p><strong>About DoseMe<\/strong><\/p>\n<p><a href=\"https:\/\/doseme-rx.com\/\">DoseMe<\/a> is a Tabula Rasa HealthCare Company (NASDAQ: TRHC) and the first company in the world to develop precision dosing software, DoseMeRx, developed specifically for clinical practice. DoseMe&rsquo;s clinical decision support solutions focus on empowering healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information, visit <a href=\"https:\/\/doseme-rx.com\/\">doseme-rx.com<\/a><\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p>This press release includes forward-looking statements that we believe to be reasonable as of today\u2019s date, including statements regarding Medication Risk Mitigation technology.&nbsp; Such statements are identified by use of the words \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cshould,\u201d and similar expressions.&nbsp; These forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this press release.&nbsp; Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, &nbsp;including those factors discussed under the caption \u201cRisk Factors\u201d in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http:\/\/ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today\u2019s date.<\/p>\n<p><strong><u>Contact<\/u><\/strong><\/p>\n<p>Dianne Semingson<\/p>\n<p><a href=\"mailto:dsemingson@TRHC.com\">dsemingson@TRHC.com<\/a><\/p>\n<p>T: 215-870-0829<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Investors<\/strong><\/p>\n<p>Bob East or Asher Dewhurst<\/p>\n<p>Westwicke Partners<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=muW-d1-pz5o7a7mZPu7Jyj-QjemejZIRP7NebqM67WvCcIERa6VqAYNJrE7QyvUUl0y_fy_HIo3V3qBTsB_YTs7vdjPpKJWk0zAmND3-J_4=\">tabularasa@westwicke.com<\/a><\/p>\n<p>T: (443) 213-0500<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announced an independent study evaluating Bayesian Forecasting (BF) programs found TRHC\u2019s DoseMe BF program &#8211; DoseMeRx &#8211; to be the most user-friendly. BF programs, such as DoseMeRx, use patient data and laboratory results to estimate a patient\u2019s ability [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":7894,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[34],"article-type":[49],"class_list":["post-4324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","tag-press-release"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DoseMeRx Receives Rating of Most User-Friendly in Clinical Study<\/title>\n<meta name=\"description\" content=\"Published in the British Journal of Clinical Pharmacology (BJCP), the purpose of the study was to evaluate three BF programs on their user-friendliness.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DoseMeRx Receives Rating of Most User-Friendly in Clinical Study\" \/>\n<meta property=\"og:description\" content=\"Published in the British Journal of Clinical Pharmacology (BJCP), the purpose of the study was to evaluate three BF programs on their user-friendliness.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study\" \/>\n<meta property=\"og:site_name\" content=\"DoseMeRx\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DoseMeApp\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-19T19:50:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-13T01:19:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/doseme-rx.com\/wp-content\/uploads\/2019\/06\/4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1120\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nicola Hunter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DoseMeApp\" \/>\n<meta name=\"twitter:site\" content=\"@DoseMeApp\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicola Hunter\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DoseMeRx Receives Rating of Most User-Friendly in Clinical Study","description":"Published in the British Journal of Clinical Pharmacology (BJCP), the purpose of the study was to evaluate three BF programs on their user-friendliness.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study","og_locale":"fr_FR","og_type":"article","og_title":"DoseMeRx Receives Rating of Most User-Friendly in Clinical Study","og_description":"Published in the British Journal of Clinical Pharmacology (BJCP), the purpose of the study was to evaluate three BF programs on their user-friendliness.","og_url":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study","og_site_name":"DoseMeRx","article_publisher":"https:\/\/www.facebook.com\/DoseMeApp\/","article_published_time":"2019-09-19T19:50:01+00:00","article_modified_time":"2021-04-13T01:19:49+00:00","og_image":[{"width":1120,"height":630,"url":"https:\/\/doseme-rx.com\/wp-content\/uploads\/2019\/06\/4.png","type":"image\/png"}],"author":"Nicola Hunter","twitter_card":"summary_large_image","twitter_creator":"@DoseMeApp","twitter_site":"@DoseMeApp","twitter_misc":{"\u00c9crit par":"Nicola Hunter","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#article","isPartOf":{"@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study"},"author":{"name":"Nicola Hunter","@id":"https:\/\/doseme-rx.com\/fr#\/schema\/person\/6c6769e1f0b02564d00c6693857210d9"},"headline":"DoseMe Bayesian Forecasting Method Receives Rating of Most User-Friendly in Clinical Study","datePublished":"2019-09-19T19:50:01+00:00","dateModified":"2021-04-13T01:19:49+00:00","mainEntityOfPage":{"@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study"},"wordCount":788,"commentCount":0,"image":{"@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#primaryimage"},"thumbnailUrl":"https:\/\/doseme-rx.com\/wp-content\/uploads\/2019\/06\/4.png","keywords":["Press Release"],"articleSection":["News &amp; Media Centre"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#respond"]}]},{"@type":"WebPage","@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study","url":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study","name":"DoseMeRx Receives Rating of Most User-Friendly in Clinical Study","isPartOf":{"@id":"https:\/\/doseme-rx.com\/fr#website"},"primaryImageOfPage":{"@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#primaryimage"},"image":{"@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#primaryimage"},"thumbnailUrl":"https:\/\/doseme-rx.com\/wp-content\/uploads\/2019\/06\/4.png","datePublished":"2019-09-19T19:50:01+00:00","dateModified":"2021-04-13T01:19:49+00:00","author":{"@id":"https:\/\/doseme-rx.com\/fr#\/schema\/person\/6c6769e1f0b02564d00c6693857210d9"},"description":"Published in the British Journal of Clinical Pharmacology (BJCP), the purpose of the study was to evaluate three BF programs on their user-friendliness.","breadcrumb":{"@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#primaryimage","url":"https:\/\/doseme-rx.com\/wp-content\/uploads\/2019\/06\/4.png","contentUrl":"https:\/\/doseme-rx.com\/wp-content\/uploads\/2019\/06\/4.png","width":1120,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/doseme-rx.com\/fr\/news-media\/articles\/doseme-rated-most-user-friendly-in-clinical-study#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/doseme-rx.com\/fr"},{"@type":"ListItem","position":2,"name":"DoseMe Bayesian Forecasting Method Receives Rating of Most User-Friendly in Clinical Study"}]},{"@type":"WebSite","@id":"https:\/\/doseme-rx.com\/fr#website","url":"https:\/\/doseme-rx.com\/fr","name":"DoseMeRx","description":"Choose us for our world-leading Bayesian dosing software. Stay with us for our best-in-class customer service.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/doseme-rx.com\/fr?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/doseme-rx.com\/fr#\/schema\/person\/6c6769e1f0b02564d00c6693857210d9","name":"Nicola Hunter","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/02e206174499150c025ce2682b2ee353f284349ff867886a3f957d50c95af6fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/02e206174499150c025ce2682b2ee353f284349ff867886a3f957d50c95af6fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/02e206174499150c025ce2682b2ee353f284349ff867886a3f957d50c95af6fe?s=96&d=mm&r=g","caption":"Nicola Hunter"},"url":"https:\/\/doseme-rx.com\/fr\/author\/nicola-hunter"}]}},"_links":{"self":[{"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/posts\/4324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/comments?post=4324"}],"version-history":[{"count":6,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/posts\/4324\/revisions"}],"predecessor-version":[{"id":7902,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/posts\/4324\/revisions\/7902"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/media\/7894"}],"wp:attachment":[{"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/media?parent=4324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/categories?post=4324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/tags?post=4324"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/doseme-rx.com\/fr\/wp-json\/wp\/v2\/article-type?post=4324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}